In this episode, the faculty review the evidence base for ammonia measurement in patients with cirrhosis, exploring whether hyperammonaemia is indicative of a poor prognosis and if erroneous measurements correlate with the efficacy of ammonia-lowering therapies. The debate also extends to the use of ammonia as a potential endpoint in randomised controlled trials for hepatic encephalopathy drugs.

Faculty

• Debbie Shawcross (Moderator)
• Rajiv Jalan (Faculty)
• Sara Montagnese (Faculty)
• Elliot Tapper (Faculty)

This EASL Studio episode is organised in collaboration with the International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).

Related episodes

• EASL Studio S5E11: Statins in cirrhosis: The window hypothesis again, or just a closed window?
• EASL Studio from EASL Congress 2023: Liver cirrhosis in 2023: Unmet needs and how to address them
• EASL Studio S4E17: Albumin in Cirrhosis: For all, some, or none?
• EASL Studio S3E12: Meeting the challenge of antimicrobial resistance (AMR) in cirrhosis: the invisible threat that lies within
• EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?
• EASL Studio S2E4: Betablockers in cirrhosis: Has Baveno consensus gone too far?

All EASL Studio Podcasts are available on EASL Campus.